Follow TVTX's trial news. Pro members can get an alert when Travere Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 849% over three years while the S&P 500 rose 80%.
“The increase is attributable to growth in sales of FILSPARI.”
| The company | Sales up 49% on the year |
| Latest filing | 8-K, Nov 2 |
Travere Therapeutics filed an 8-K reporting a change of CEO
TVTX closed −4.1% the next session (Sep 22) on 2.1x normal volume.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +4.0% on average, higher 3 of 4 times.
CEO Eric M. Dube sold 243,735 shares on Oct 15, under a planned sale. 50 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
TVTX is #64 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 64 |
Share count against a year before: TVTX +6%, BMRN +0.8%, AUPH +1.2%, BBIO +2.2%.
Expected to report Thu Feb 18, after the close (in 100 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $224.6M, 36% more than a year ago; a loss of $0.55 a share.
“The increase is primarily attributable to advancement of the Phase 3 HARMONY Study and manufacturing of pegtibatinase for classical homocystinuria (HCU).”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $220M | $161M | $113M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 2)
No outlook figures read from this release.
“The difference is primarily attributable to commercial investments supporting the recent launch of FILSPARI in FSGS, as well as ongoing commercialization efforts in IgAN.”
From its results filing (SEC filing · Nov 2)
Sales grew 20% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 13% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -5.6% | +0.3% | +4.8% |
| Aug 4, 2026 | +10.7% | +12.0% | +7.5% |
| May 4, 2026 | +1.9% | -0.2% | -3.1% |
Sales grew in five of the last seven years, to $491M in 2025. It lost money in each of the eight years.
RSI 48.3, MACD above signal, below its 50-day, above its 200-day. Not scored.
One insider sold $43K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: TVTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
“The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological change.”
TVTX scores 7 today, which Breakaway calls Average. It is #64 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 849% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TVTX scores 7 today, which Breakaway calls Average (6 to 10). That is #64 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TVTX's 7.
One insider sold $43K across 1 filing in the last 6 months. No open-market buys on record. The newest is Christopher R. Cline, Chief Financial Officer, who sold $43K on Sep 2.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.